Revolutionary Breakthroughs in ALK-positive Non-Small Cell Lung Cancer Therapy Revealed in DelveInsight’s Pipeline Analysis | Companies – GlaxoSmithKline, Novartis, AstraZeneca, Pfizer, and Others
DelveInsight’s, “ALK-positive Non-Small Cell Lung Cancer Pipeline Insights, 2023,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the ALK-positive Non-Small Cell Lung Cancer pipeline landscape. It covers the ALK-positive Non-Small Cell Lung Cancer pipeline drug profiles, including ALK-positive Non-Small Cell Lung Cancer clinical trials and nonclinical stage products. It also covers the ALK-positive Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
To explore more information on the latest breakthroughs in the ALK-positive Non-Small Cell Lung Cancer Pipeline treatment landscape of the report, click here @ ALK-positive Non-Small Cell Lung Cancer Pipeline Outlook
ALK-positive Non-Small Cell Lung Cancer Overview
ALK-positive lung cancer is a non-small cell lung cancer (NSCLC) that harbors a mutation in a gene called anaplastic lymphoma kinase (ALK). More precisely, it’s a gene rearrangement—a fusion of ALK and another gene, echinoderm microtubule-associated protein-like 4 (EML4). This abnormal fusion causes cell enzymes (proteins) to send signals to mutated cancer cells telling them to divide and multiply more quickly than usual, which spreads the disease.
Key takeaways from the ALK-positive Non-Small Cell Lung Cancer Pipeline Report
- Over 30+ ALK-positive Non-Small Cell Lung Cancer companies are evaluating 30+ ALK-positive Non-Small Cell Lung Cancer pipeline therapies in various stages of development, and their anticipated acceptance in the ALK-positive Non-Small Cell Lung Cancer market would significantly increase market revenue.
- The leading ALK-positive Non-Small Cell Lung Cancer Companies includes GlaxoSmithKline, Novartis, AstraZeneca, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Suzhou Zelgen Biopharmaceuticals Co.,Ltd, Ariad Pharmaceutica, Takeda, Chia Tai Tianqing Pharmaceutical Group, Akeso, and others.
- Promising ALK-positive Non-Small Cell Lung Cancer Pipeline Therapies includes Ceritinib, Lortlatinib, PF-06463922, Crizotinib, Ribociclib, Phase I: X-396 (ensartinib), Ganetespib, LDK378, Nivolumab, X-396 (ensartinib), and others.
- On May, 2023, The Food and Drug Administration approved olaparib (Lynparza, AstraZeneca Pharmaceuticals LP) in combination with abiraterone and prednisone (or prednisolone) for adult patients with metastatic castration-resistant prostate cancer (mCRPC) that is deleterious or suspected to be deleterious BRCA-mutated (BRCAm).
For further information, refer to the detailed ALK-positive Non-Small Cell Lung Cancer Unmet Needs, ALK-positive Non-Small Cell Lung Cancer Market Drivers, and ALK-positive Non-Small Cell Lung Cancer Market Barriers, click here for ALK-positive Non-Small Cell Lung Cancer Ongoing Clinical Trial Analysis
ALK-positive Non-Small Cell Lung Cancer Emerging Drugs Profile
- Ensartinib: Betta Pharmaceuticals/Xcovery
Ensartinib is a potential best-in-class compound for the first-line treatment of anaplastic lymphoma kinase (ALK)–positive non-small cell lung cancer (NSCLC). Ensartinib has shown promising clinical activity in patients with ALK-positive NSCLC in a phase 1/2 trial. A single-arm phase 2 trial of ensartinib as second-line treatment for patients with ALK-positive NSCLC previously treated with crizotinib has been completed in 156 Chinese patients, and a New Drug Application has been filed in China. An ensartinib global first-line phase 3 registration trial vs crizotinib is ongoing.
- TQ-B3139 – Chia Tai Tianqing Pharmaceutical Group
TQ-B3139 is an orally available, small molecule inhibitor of the receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and hepatocyte growth factor receptor (c-Met; HGFR), with potential antineoplastic activity. Upon oral administration, TQ-B3139 binds to and inhibits the activity of ALK and c-Met, which leads to the disruption of ALK- and c-Met-mediated signaling and the inhibition of cell growth in ALK- and c-Met-expressing tumor cells. ALK and c-Met, overexpressed or mutated in many tumor cell types, play key roles in tumor cell proliferation, survival, invasion and metastasis.
Request a sample and discover the recent advances in ALK-positive Non-Small Cell Lung Cancer Ongoing Clinical Trial Analysis and Medications, click here @ ALK-positive Non-Small Cell Lung Cancer Treatment Landscape
ALK-positive Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment
There are approx. 30+ key companies which are developing the therapies for ALK-positive Non-Small Cell Lung Cancer. The companies which have their ALK-positive Non-Small Cell Lung Cancer drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Betta Pharmaceuticals/Xcovery, Chia Tai Tianqing Pharmaceutical Group, Merck, Pfizer etc.
Dive deep into rich insights for drugs for ALK-positive Non-Small Cell Lung Cancer Pipeline, click here @ ALK-positive Non-Small Cell Lung Cancer Unmet Needs and Analyst Views
Scope of the ALK-positive Non-Small Cell Lung Cancer Pipeline Report
- Coverage- Global
- ALK-positive Non-Small Cell Lung Cancer Companies- GlaxoSmithKline, Novartis, AstraZeneca, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Suzhou Zelgen Biopharmaceuticals Co.,Ltd, Ariad Pharmaceutica, Takeda, Chia Tai Tianqing Pharmaceutical Group, Akeso, and others.
- ALK-positive Non-Small Cell Lung Cancer Pipeline Therapies- Ceritinib, Lortlatinib, PF-06463922, Crizotinib, Ribociclib, Phase I: X-396 (ensartinib), Ganetespib, LDK378, Nivolumab, X-396 (ensartinib), and others.
- ALK-positive Non-Small Cell Lung Cancer Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Got Queries? Find out the related information on ALK-positive Non-Small Cell Lung Cancer Mergers and acquisitions, ALK-positive Non-Small Cell Lung Cancer Licensing Activities @ ALK-positive Non-Small Cell Lung Cancer Emerging Drugs, and Recent Trends
Table of Content
- Introduction
- Executive Summary
- ALK-positive Non-Small Cell Lung Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- ALK-positive Non-Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- ALK-positive Non-Small Cell Lung Cancer Collaboration Deals
- Late Stage Products (Phase III)
- Ensartinib: Betta Pharmaceuticals/Xcovery
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Bintrafusp alfa: EMD Serono/GlaxoSmithKline/Merck
- Early Stage Products (Phase I)
- PLB1003: Beijing Pearl Biotechnology Limited Liability Company
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- Drug profiles in the detailed report…..
- Inactive Products
- ALK-positive Non-Small Cell Lung Cancer Key Companies
- ALK-positive Non-Small Cell Lung Cancer Key Products
- ALK-positive Non-Small Cell Lung Cancer- Unmet Needs
- ALK-positive Non-Small Cell Lung Cancer- Market Drivers and Barriers
- ALK-positive Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
- ALK-positive Non-Small Cell Lung Cancer Analyst Views
- ALK-positive Non-Small Cell Lung Cancer Key Companies
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
